In particular, the rate of hip, pelvis, wrist, or humerus fractures was 101 per 1,000 person-years in the opioid group, compared with 19 per 1,000 person-years in the coxib
group and 26 per 1,000 person-years in the NSAID group.
01) for patients treated with coxibs
(alone or in addition to tNSAIDs or glucocorticoids), and 3.
Patients on coxibs
, tNSAIDs, or glucocorticoids formed the any-inhibitor group (n = 253).
This helped illuminate the role that all NSAIDs--even coxibs
like celecoxib (Celebrex[R]) and valdecoxib (Bextra[R])--may play in hypervolemic hyponatremia among endurance athletes.
76), but a lower risk was observed for coxib
users (HR, 0.
Last column refers to number of patients that need to be treated with a coxib
for a year to prevent 1 upper GI complication, except where not applicable.
Celecoxib is the first coxib
product to target only the COX-2 enzyme.
Following FDA approval for the acute treatment of migraine in late March, VIOXX is now approved for treating more types of painful conditions than any other coxib
in the United States and remains the only coxib
approved to relieve migraine pain and associated migraine symptoms.
Even more interesting, in a high-risk patient with a history of ulcer bleeding, 60% said they would recommend a proton pump inhibitor with a coxib
and aspirin--even though there are no published data to support this strategy, and 24%, disturbingly, would choose a coxib
and aspirin without gastroprotection," Dr.
Bob joins us at an exciting juncture as we build on the leadership position we have established in the coxib
arena with this year's launches of Bextra and Dynastat.
in the United States currently has indications for chronic low-back pain, acute gouty arthritis or ankylosing spondylitis.
But experts sharply disagree on whether the findings on this latest addition to the class of selective cyclo-oxygenase 2 (COX-2) inhibitors truly exonerate the coxib
of its role in potentiating myocardial infarctions and gastrointestinal adverse effects.